Thyroid Cancers

A Look Back at FDA News from February 2020

March 04, 2020

In February 2020, the FDA gave indications to multiple therapies meant for treatment of solid tumor and hematologic malignancies. FDA action included 10 Priority Reviews, 2 Breakthrough Therapy designations, and 2 Fast Track designations.

ACCC Creates Resources for Multidisciplinary Practices to Prepare for Growing Geriatric Cancer Population

February 25, 2020

To help clinicians cope with an increasing number of geriatric patients with cancer, the Association of Community Cancer Centers is address­ing this problem with a 2-pronged approach that focuses on the delivery of care and diagnostic assessment.

FDA Grants Priority Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer

January 29, 2020

The New Drug Application for selpercatinib was granted FDA Priority Review for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, based on data from the phase I/II LIBRETTO-001 trial, Eli Lilly and Company announced in a press release.

Analysis Finds No Association Between Sorafenib Use and Sarcopenia in Thyroid Cancer

January 27, 2020

A new retrospective exploratory analysis has found no association between treatment with sorafenib and the development of sarcopenia among patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. However, this analysis, which was published recently in Thyroid, did find that sorafenib had a significant effect on muscle mass.

Lenvatinib Yields Survival Benefit Over Palliative Care for Anaplastic Thyroid Cancer

January 20, 2020

Lenvatinib demonstrated a longer median overall survival compared with palliative therapy in patients with stage IVC anaplastic thyroid cancer, a rare disease for which the survival rate has not improved in roughly 20 years. The introduction of targeted therapy to the treatment landscape for anaplastic thyroid cancer has been challenging in the past because some patients do not have time to undergo therapy on a clinical trial because the process is time-consuming, and the procedure for study enrollment may exceed time to progression.

First Randomized Clinical Trial Evaluating Geriatric Assessment Reveals High Satisfaction With Communication About Aging-Related Concerns

January 18, 2020

Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.

Telehealth Delivers Access to Care and Cutting-Edge Clinical Research to Rural Areas

January 11, 2020

The present and future benefits of telehealth in oncology can be observed through Tahoe For­est Cancer Center and its affiliation with the UC Davis Cancer Center, use of other remote clinics, and participation in virtual tumor boards. Even though there are roadblocks to telehealth reaching more locations and more patients, the potential benefit warrants the time needed to get over those hurdles.

Thyroid Cancer Diagnoses Decline Following Shift in Clinical Screening Practices

December 24, 2019

The incidence of thyroid cancer in the United States may be on decline since the rise in thyroid cancer diagnoses observed between 1974 and 2013. This finding is based on observational analysis of data from the Surveillance, Epidemiology, and End Results 13 registry, which were recently published in JAMA.

Rethinking the Treatment of Aggressive Thyroid Cancer

December 19, 2019

Shlomo Koyfman, MD, discusses registry data on thyroid cancer and how data from the registry can improve practice for oncologists.

Lenvatinib Lands New Indication for Differentiated Thyroid Cancer in China

December 06, 2019

Lenvatinib is now indicated for the treatment of differentiated thyroid cancer in China as a result of application acceptance by the National Medical Products Administration of China, according to a press release from Eisai Co., Ltd.